NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

CompletedN/A

Sponsor: Pfizer

Conditions: Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration Resistant Prostate Cancer (mCRPC)

Interventions: abiraterone, enzalutamide, docetaxel, apalutamide, cabazitaxel

Countries: Finland

Comprehensive understanding of the epidemiology and disease burden of metastatic prostate cancer patients in Finland is lacking. This study will address the following questions: * What are the demographic and clinical characteristics of metastatic prostate cancer patients? * How are metastatic prostate cancer patients currently treated and how effective are these treatments? * How does the development of castration-resistance affect patient outcomes? * What is the economic burden of metastatic prostate cancer?

Eligibility overview

Sex: MALE

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Diagnosis of prostate cancer between 1/1/2007 - 12/31/2022
* Resident of Pirkanmaa at index date (diagnosis of mCSPC and/or mCRPC)
* Detection of metastatic prostate cancer

Exclusion Criteria:

* Prevalent mCSPC and mCRPC patients (mCSPC or mCRPC diagnosis date before 1/1/2014
* Patient has another cancer diagnosis or the patient has received chemotherapy other than docetaxel or cabazitaxel within 2 years of mPC diagnosis.

Locations (1)

Helsinki, Finland